Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Curing hep C slashes risk of death for those with liver cancer history
This finding from a recent study applies to those who do not have cirrhosis when they are treated for the virus.
A new classification system may more accurately reflect liver-related death trends in the United States.
This held true regardless of the type of hep C treatment—interferon-based or direct-acting antiviral.
In the era of highly effective treatments for both viruses, HIV doesn’t speed the advancement of cirrhosis.
South Korean researchers found no difference in the rates of liver cancer, liver transplant or death based on the treatment used.
Researchers call for greater use of noninvasive measures of fatty liver disease in this population to identify those at risk.
Researchers analyzed autopsies among people with HIV who died in New York City since 1984.
Researchers have presented findings from the first large cohort of people followed over a lengthy period to assess this connection.
This is according to an analysis of nearly 5,000 Italians recently treated for the virus.
A new study appears to resolve controversy over hep C treatment’s association with mortality risk.
An analysis conducted in Taiwan analyzed health outcomes over more than a decade.
Researchers reached this conclusion after reviewing data on more than 30,000 people.
Scientists have firmly established an association between direct-acting antiviral treatment and a lower risk of liver cancer and death.
The drug is still associated with a lower liver cancer rate than Baraclude.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.